Howard Safran

Summary

Affiliation: Rhode Island Hospital
Country: USA

Publications

  1. pmc A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
    Humera Khurshid
    The Brown University Oncology Group, Providence RI, USA
    Front Oncol 2:56. 2012
  2. ncbi request reprint Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer
    H Safran
    Brown University Oncology Group, Providence, Rhode Island
    Cancer Invest 19:1-7. 2001
  3. ncbi request reprint Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma
    Howard Safran
    Brown University Oncology Group, Providence, RI, USA
    Int J Radiat Oncol Biol Phys 67:405-9. 2007
  4. ncbi request reprint Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004
  5. ncbi request reprint Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:670-7. 2004
  6. ncbi request reprint HER family inhibitors in pancreatic cancer: current status and future directions
    David Berz
    The Brown University Oncology Group, 164 Summit Avenue, Providence, RI 02906, USA
    Expert Opin Ther Targets 11:337-47. 2007
  7. ncbi request reprint Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity
    Howard Safran
    Brown University Oncology Group, Providence, RI, USA
    Int J Radiat Oncol Biol Phys 70:391-5. 2008
  8. doi request reprint Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer
    Howard Safran
    Department of Medicine, The Miriam Hospital, Brown University Oncology Group, Providence, Rhode Island 02906, USA
    Am J Clin Oncol 31:140-4. 2008
  9. ncbi request reprint Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer
    Howard Safran
    The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Crit Rev Oncol Hematol 43:57-62. 2002
  10. ncbi request reprint Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial
    Howard Safran
    The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Int J Radiat Oncol Biol Phys 54:137-41. 2002

Collaborators

Detail Information

Publications38

  1. pmc A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer
    Humera Khurshid
    The Brown University Oncology Group, Providence RI, USA
    Front Oncol 2:56. 2012
    ..Due to these toxicities the Brown University Oncology Group Data Safety Monitoring Board terminated the study. Conclusion: Dasatinib could not be safely combined with concurrent chemoradiation for stage 3 lung cancer due to pneumonitis...
  2. ncbi request reprint Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer
    H Safran
    Brown University Oncology Group, Providence, Rhode Island
    Cancer Invest 19:1-7. 2001
    ..Esophagitis was less severe than expected and prophylactic enteral feeding tubes were not necessary. Additional effective systemic treatments are needed to reduce the development of distant metastases...
  3. ncbi request reprint Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma
    Howard Safran
    Brown University Oncology Group, Providence, RI, USA
    Int J Radiat Oncol Biol Phys 67:405-9. 2007
    ..To determine the overall survival for patients with locally advanced, HER2 overexpressing, esophageal adenocarcinoma receiving trastuzumab, paclitaxel, cisplatin, and radiation on a Phase I-II study...
  4. ncbi request reprint Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:706-12. 2004
    ..To determine the response rate and toxicities of Herceptin and gemcitabine for patients with metastatic pancreatic adenocarcinomas that overexpress HER-2/neu...
  5. ncbi request reprint Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study
    Howard Safran
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 22:670-7. 2004
    ..To conduct a phase I study incorporating trastuzumab with paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus...
  6. ncbi request reprint HER family inhibitors in pancreatic cancer: current status and future directions
    David Berz
    The Brown University Oncology Group, 164 Summit Avenue, Providence, RI 02906, USA
    Expert Opin Ther Targets 11:337-47. 2007
    ..This article reviews clinical trials of HER family inhibitors in pancreatic cancer, discusses the role of these agents in the management of patients and outlines future directions for pancreatic cancer management...
  7. ncbi request reprint Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity
    Howard Safran
    Brown University Oncology Group, Providence, RI, USA
    Int J Radiat Oncol Biol Phys 70:391-5. 2008
    ..To determine the feasibility and toxicity of the addition of cetuximab with paclitaxel, carboplatin, and radiation for patients with esophagogastric cancer on a Phase II study...
  8. doi request reprint Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer
    Howard Safran
    Department of Medicine, The Miriam Hospital, Brown University Oncology Group, Providence, Rhode Island 02906, USA
    Am J Clin Oncol 31:140-4. 2008
    ..To evaluate the safety/tolerability and potential antitumor activity of lapatinib, at dose ranges of 1000 to 1500 mg/d, in combination with gemcitabine and gemcitabine/oxaliplatin (GEMOX) in patients with advanced pancreaticobiliary cancer...
  9. ncbi request reprint Paclitaxel as a radiation sensitizer for locally advanced pancreatic cancer
    Howard Safran
    The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Crit Rev Oncol Hematol 43:57-62. 2002
    ..The addition of gemcitabine to paclitaxel and radiation has also demonstrated promising preliminary activity and a phase II study by the RTOG is being initiated...
  10. ncbi request reprint Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial
    Howard Safran
    The Brown University Oncology Group, Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Int J Radiat Oncol Biol Phys 54:137-41. 2002
    ..To determine the maximum tolerated dose (MTD) and dose-limiting toxicities of gemcitabine, paclitaxel, and concurrent radiation for pancreatic cancer...
  11. ncbi request reprint Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study
    Devon Evans
    The Brown University Oncology Group, Providence, Rhode Island 02906, USA
    Cancer Invest 25:445-8. 2007
    ..The objectives of this Phase II study were to determine the response rate, toxicity, and survival for patients with metastatic esophagogastric cancer treated with this regimen...
  12. ncbi request reprint Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study
    Tom Dipetrillo
    Brown University Oncology Group, Providence, RI, USA
    Am J Clin Oncol 29:376-9. 2006
    ..To determine the maximal tolerated dose (MTD) and dose limiting toxicities of poly(l-glutamic acid)-paclitaxel (PPX) and concurrent radiation (PPX/RT) for patients with esophageal and gastric cancer...
  13. ncbi request reprint Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer
    James Y Tsai
    Brown University Oncology Group, Providence, Rhode Island, USA
    Am J Clin Oncol 28:329-33. 2005
    ....
  14. doi request reprint Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial
    Thomas DiPetrillo
    The Brown University Oncology Group, Providence, Rhode Island, USA
    Am J Clin Oncol 35:64-7. 2012
    ..To evaluate the pathologic complete response (CR) rate and safety of paclitaxel poliglumex (PPX), cisplatin, and concurrent radiation for patients with esophageal cancer...
  15. ncbi request reprint A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer
    Devon Evans
    Brown University Oncology Group, Providence, RI, USA
    Am J Clin Oncol 30:346-9. 2007
    ..The Brown University Oncology Group initiated a phase I study to determine the maximum tolerated dose of weekly docetaxel, oxaliplatin, and capecitabine...
  16. ncbi request reprint Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study
    David Iannitti
    Brown University Oncology Group, Providence, RI, USA
    Am J Clin Oncol 28:570-5. 2005
    ....
  17. doi request reprint Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer
    Tom Dipetrillo
    Brown University Oncology Group, Providence, RI 02906, USA
    Int J Radiat Oncol Biol Phys 82:124-9. 2012
    ....
  18. doi request reprint Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis
    Ariel Birnbaum
    Brown University Oncology Group, Providence RI, USA
    Am J Clin Oncol 33:144-7. 2010
    ..To determine the feasibility and toxicity of the addition of cetuximab to paclitaxel, carboplatin, and concurrent radiation for patients with head and neck cancer...
  19. doi request reprint Phase I study of hepatic arterial infusion of oxaliplatin in advanced hepatocellular cancer: a brown university oncology group study
    Ritesh Rathore
    Division of Hematology Oncology, Roger Williams Hospital, Providence, Rhode Island 02908, USA
    Am J Clin Oncol 33:43-6. 2010
    ..We performed a phase I study to evaluate the feasibility and determine the maximally tolerated dose of hepatic arterial infusion (HAI) of oxaliplatin in advanced hepatocellular carcinoma (HCC)...
  20. ncbi request reprint Paclitaxel and concurrent radiation in upper gastrointestinal cancers
    Maria Constantinou
    Brown University Oncology Group, Providence, Rhode Island, USA
    Cancer Invest 21:887-96. 2003
    ..Ongoing trials in pancreatic cancer are investigating the addition of gemcitabine to paclitaxel and radiation and incorporating molecular targeting agents...
  21. ncbi request reprint Multimodality treatment of esophageal cancer: a review of the current status and future directions
    Thomas Ng
    Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Curr Oncol Rep 8:174-82. 2006
    ..Advances in radiation oncology and surgery may decrease morbidity and mortality from trimodality therapy, improving patient outcome...
  22. ncbi request reprint Chemotherapy for pancreatic cancer
    James Y Tsai
    Department of Medicine, Brown Medical School, USA
    Med Health R I 87:132-4. 2004
  23. ncbi request reprint A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma
    Wallace Akerley
    Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA
    Cancer 95:2000-5. 2002
    ..We conducted a Phase I study of weekly paclitaxel (P) and carboplatin (C) in patients with advanced malignancies to determine the maximum tolerated dose (MTD) of this combination...
  24. doi request reprint 37. ADXS11-001, mitomycin, 5-FU and radiation for anal cancera A phase I/II study
    Howard Safran
    The Brown University Oncology Research Group, Brown University, Providence, RI, USA
    Sex Health 10:588. 2013
    ..Conclusions: ADXS11-001 is a highly novel form of immunotherapy designed to generate an immune response against HPV transformed cells. Accrual is continuing to evaluate safety and efficacy for patients with anal cancer. ..
  25. ncbi request reprint Combined modality therapy for pancreatic cancer
    James Y Tsai
    Brown University Oncology Group, Providence, RI, USA
    Semin Oncol 30:71-9. 2003
    ..Molecular agents are being combined with chemoradiation in an attempt to delay or prevent systemic progression...
  26. pmc Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma
    Masafumi Shimoda
    The Warren Alpert Medical School of Brown University, Providence, RI, USA
    J Hepatol 56:1129-35. 2012
    ....
  27. ncbi request reprint Status of treatment for advanced gastric carcinoma
    James Y Tsai
    Department of Medicine, The Miriam Hospital, 164 Summit Avenue, Providence, RI 02906, USA
    Curr Oncol Rep 5:210-8. 2003
    ..It is anticipated that the development of these active new agents will ultimately improve survival for patients with advanced gastric cancer...
  28. ncbi request reprint Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma
    Kevin S Palumbo
    Department of Medicine, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island 02903, USA
    Pancreas 25:39-44. 2002
    ..Pancreatic adenocarcinoma is among the top 10 leading causes of death due to cancer in the United States. The lack of reliable and sensitive biomarkers for this disease makes it difficult to render an early diagnosis...
  29. ncbi request reprint Evaluation and treatment of hepatic metastases from unknown GI primary
    Nadia Ramdin
    Department of Hematology Oncology, The Miriam Hospital, 168 Summit Ave, Providence, RI 02908, USA
    Med Health R I 85:181-3. 2002
  30. pmc Cellular immunotherapy for refractory hematological malignancies
    John L Reagan
    Division of Hematology Oncology, Rhode Island Hospital The Miriam Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, USA
    J Transl Med 11:150. 2013
    ..The end goal of cellular therapy is not engraftment but instead is the purposeful rejection of donor cells so as to elicit a potent immune reaction that appears to break host tumor tolerance...
  31. pmc Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer
    Jaroslaw T Hepel
    Department of Radiation Oncology, Rhode Island Hospital, Brown University Providence, RI, USA
    Front Oncol 2:124. 2012
    ..A phase I/II trial to evaluate the clinical safety and efficacy of this approach is being undertaken...
  32. pmc Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial
    Damian E Dupuy
    Department of Diagnostic Imaging, The Warren Alpert Medical School at Brown University, Providence, RI 02903, USA
    Cancer 116:989-97. 2010
    ..The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease...
  33. ncbi request reprint ErbB2 degradation mediated by the co-chaperone protein CHIP
    Pengcheng Zhou
    Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:13829-37. 2003
    ....
  34. ncbi request reprint Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 56:31-7. 2003
    ..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer...
  35. doi request reprint Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
    William F Regine
    Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
    JAMA 299:1019-26. 2008
    ..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil...
  36. ncbi request reprint Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial
    Ramesh K Ramanathan
    University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232, USA
    Cancer Invest 22:858-65. 2004
    ....
  37. ncbi request reprint Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer
    Wallace Akerley
    Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah 84115, USA
    Cancer 107:1050-4. 2006
    ..The purpose of the current study was to evaluate the efficacy and tolerance of the noncisplatin-based combination of paclitaxel and gemcitabine administered weekly for patients with untreated metastatic nonsmall cell lung cancer (NSCLC)...
  38. ncbi request reprint A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone
    Wallace Akerley
    Boston University Medical Center, Oncology Hematology, Boston, Massachusetts 02118, USA
    Cancer 94:1654-60. 2002
    ..2 MBq/kg on Day 1. Courses were repeated every 12 weeks. Response assessment was based on a change in the serum prostate specific antigen (PSA) levels, correlated with change in measurable disease and bone scan appearance...